Caribou Biosciences, Inc.
CRBUHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeCaribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. The company carries a $57.1M market cap, placing it firmly in the micro-cap category. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies.
Market Cap
$57.1M
Beta
2.31
P/E (TTM)
—
P/E (Fwd)
-0.59
EPS (TTM)
$-1.08
EPS (Fwd)
$-0.90
ROE
-78.3%
ROA
-36.9%
Cash
$112.3M
Total Debt
$26.7M
Free CF
-$59.6M
52W Change
-78.2%
Annual Financials
Cash vs Debt
Where CRBU stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CRBU finished 72.62% below its 150-day moving average ($1.68) and 72.62% below its 200-day moving average ($1.68). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CRBU overbought or oversold?
At the October 20, 2026 close, CRBU's RSI(14) was 8.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Caribou Biosciences, Inc. holds $112.3M in cash against $26.7M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$59.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -78.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $13.9M to $11.2M.
With a beta above 1.5, CRBU tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, CRBU has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Caribou Biosciences, Inc.'s trajectory.